Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving aTyr Pharma, Inc. following the failure of its Phase 3 clinical trial results, which significantly impacted the company's stock price [1][3]. Group 1: Company Overview - aTyr Pharma, Inc. is a publicly traded company on NASDAQ under the ticker ATYR [1]. - The company recently announced topline results from the Phase 3 EFZO-FIT™ study of efzofitimod, which involved 268 patients with pulmonary sarcoidosis [3]. Group 2: Clinical Trial Results - The Phase 3 EFZO-FIT™ study did not meet its primary endpoint, leading to a significant decline in aTyr's stock price [3]. - Following the announcement of the trial results, aTyr's stock price dropped by $5.02 per share, representing an 83.25% decrease, closing at $1.01 per share on September 15, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding possible securities fraud or other unlawful practices by aTyr and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Points - A class action lawsuit has been filed against Fly-E Group, Inc. for alleged securities fraud and unlawful business practices [2] - Investors have until November 7, 2025, to request appointment as Lead Plaintiff if they purchased Fly-E securities during the Class Period [2] - Fly-E reported a 32% decrease in net revenues for Q1 FY 2026, attributed to a decline in total units sold and recent lithium-battery accidents involving E-Bikes and E-Scooters [4] - Following the revenue report, Fly-E's stock price plummeted by $6.76, or 87.11%, closing at $1.00 per share on August 15, 2025 [4] Company Information - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [5]

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Cytokinetics a ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by DexCom, Inc. following allegations from a short report that highlighted serious issues with the company's G7 glucose monitoring system [1][3]. Group 1: Allegations and Impact - Hunterbrook Media published a report titled "Dexcom's Fatal Flaws," claiming that DexCom made unauthorized design changes to a critical component of the G7 system, leading to hospitalizations and fatalities due to inaccurate glucose readings [3]. - Following the release of the Hunterbrook report, DexCom's stock price dropped by $8.99 per share, representing an 11.76% decline, closing at $67.45 per share on September 19, 2025 [4]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking to represent investors of DexCom who may have been affected by the alleged misconduct, urging them to come forward [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Coty Inc. and its executives following disappointing financial results and guidance [1][3]. Financial Performance - On August 20, 2025, Coty reported an unexpected loss for its full fiscal year 2025 and fourth quarter, which was attributed to challenges in the beauty market, including consumer behavior and policy changes [3]. - The Chief Financial Officer of Coty indicated that sluggish sales were due to value-seeking behavior, innovation fatigue among consumers, and changes in anti-theft and immigration policies [3]. Stock Market Reaction - Following the announcement of the financial results, Coty's stock price dropped by $1.05 per share, representing a decline of 21.6%, closing at $3.81 per share on August 21, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR, which led to a significant drop in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Soleno Therapeutics, Inc. and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Scorpion Capital that criticized Soleno's only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [3]. Group 2: Stock Price Impact - Following the release of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, which is a decline of 7.41%, closing at $71.63 per share on the same day [3]. Group 3: Company Background - Soleno Therapeutics, Inc. is a company that has been under scrutiny due to concerns regarding its product and business practices, which may affect investor confidence and market performance [1][3].

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for alleged securities fraud and unlawful business practices, following a significant decline in the company's net revenues attributed to recent lithium-battery accidents involving E-Bikes and E-Scooters [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Fly-E and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 7, 2025, to request the Court to appoint them as Lead Plaintiff if they purchased Fly-E securities during the Class Period [2]. Group 2: Financial Performance - On August 14, 2025, Fly-E reported a 32% decrease in net revenues for the first quarter of fiscal year 2026, primarily due to a decrease in total units sold [2]. - Following the revenue announcement, Fly-E's stock price plummeted by $6.76 per share, or 87.11%, closing at $1.00 per share on August 15, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Matrix Service Company and its officers or directors [1] Financial Performance - For Q4 of fiscal year 2025, Matrix reported non-GAAP earnings per share of -$0.28, missing consensus estimates by $0.29 [2] - Revenue for the quarter was $216.4 million, falling short of consensus estimates by $15.85 million [2] - The company cited a $14.9 million impact on net income due to several issues, including labor cost overruns, contract disputes, unfavorable court decisions, and restructuring costs [2] Stock Market Reaction - Following the announcement of the financial results, Matrix's stock price dropped by $1.98 per share, or 13.89%, closing at $12.27 per share on September 10, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fluor Corporation and its executives following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On August 1, 2025, Fluor reported Q2 2025 financial results and lowered its full-year guidance, attributing the poor performance to rising costs in infrastructure projects due to subcontractor design errors, price increases, and scheduling delays [3]. - Customers are reportedly reducing capital spending, further impacting Fluor's financial outlook [3]. - Following the announcement, Fluor's stock price decreased by $15.35 per share, or 27.03%, closing at $41.42 per share on August 5, 2025 [3]. Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of Fluor investors regarding possible securities fraud or other unlawful practices by the company and its officers/directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]. Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Freeport-McMoran Inc. and its officers or directors [1]. Group 1: Company Operations - On September 9, 2025, Freeport announced the suspension of mining activities at its Grasberg Block Cave operation in Indonesia due to a blockage caused by wet material, which trapped seven workers [3]. - Following the announcement, Freeport's stock price decreased by $2.80 per share, representing a decline of 5.99%, closing at $43.87 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Freeport regarding the alleged securities fraud or other unlawful practices [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4].